Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Celcuity Inc. CELC NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$108.75
-10%

Celcuity Inc. (CELC) is a Biotechnology company in the Healthcare sector, currently trading at $120.85. It has a SharesGrow Score of 34/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Analyst consensus target is CELC = $109 (-10% upside).

Valuation: CELC trades at a trailing Price-to-Earnings (P/E) of -35 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.36.

Net income is $177M (loss), growing at -62.6%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $195M against $101M equity (Debt-to-Equity (D/E) ratio 1.94, leveraged). Current ratio is 10.55 (strong liquidity). Debt-to-assets is 41.9%. Total assets: $467M.

Analyst outlook: 8 / 9 analysts rate CELC as buy (89%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 57/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 33/100 (Fail), Moat 40/100 (Fail), Future 68/100 (Pass), Income ?/100 (Fail).

$108.75
▼ 10.01% Downside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Celcuity Inc., the average price target is $108.75, with a high forecast of $126.00, and a low forecast of $77.00.
Highest Price Target
$126.00
Average Price Target
$108.75
Lowest Price Target
$77.00

CELC SharesGrow Score Overview

43/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 57/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 68/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CELC

~
VALUE Partial
57/100
CELC trades at a trailing Price-to-Earnings (P/E) of -35 (S&P 500 average ~25). Forward PEG 0.36 — Peter Lynch undervalued (≤1.0). Trailing PEG 11.66. Analyst consensus target is $109, implying -9.8% from the current price $121. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
CELC: +0%/yr revenue is, -62.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet CELC: Debt-to-Equity (D/E) ratio 1.94 (leveraged), Current ratio is 10.55 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
CELC: Gross margin is 0% (+0 pp trend), $6B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
68/100
Analyst outlook: 8 / 9 analysts rate CELC as buy (89%). Analyst consensus target is $109 (-9.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range7.575-120.315
Volume482.65K
Avg Volume (30D)736.5K
Market Cap$5.84B
Beta (1Y)0.42
Share Statistics
EPS (TTM)-3.78
Shares Outstanding$52.54M
IPO Date2017-09-20
Employees87
CEOBrian F. Sullivan
Financial Highlights & Ratios
Gross Profit$-167K
EBITDA$-172.19M
Net Income$-177.04M
Operating Income$-172.19M
Total Cash$441.5M
Total Debt$195.38M
Net Debt$29.68M
Total Assets$466.56M
Price / Earnings (P/E)-32
Analyst Forecast
1Y Price Target$116.00
Target High$126.00
Target Low$77.00
Upside-4.0%
Rating ConsensusBuy
Analysts Covering9
Buy 89% Hold 11% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS15102K1007

Price Chart

Track all markets on TradingView
CELC
Celcuity Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
7.58 52WK RANGE 120.32

People Also View

EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.76
+0.91%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
 ADAG
ADAG
Adagene Inc.
$3.81
-0.78%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message